Contribute Try STAT+ Today

SAN FRANCISCO — After three decades working on cell and gene therapy, David DiGiusto has expertise that’s hard to find. So hard to find, in fact, that one cancer immunotherapy company stopped at nothing to try to hire him.

First, DiGiusto was told he could name his salary. Next, he was told he could name his desired equity stake. When those offers didn’t work, the chairman of the board tried to woo DiGiusto with a last-ditch deal: He’d buy DiGiusto a $10,000 Omega Speedmaster wristwatch — if only he’d join the company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • And yet,
    cross referencing his linkedin profile with his pubmed record, it seems he went through both his MS and PhD without publishing one single first author research article (from where I come from, that wouldn’t qualify you for a PhD). And, although, being research professor (how that happened?) at City of Hope institute since 1998, he didn’t publish a single research article (just a few reviews) till 2006! That’s 8 years without delivering any actual new research!
    I wish academic institutions, biotechs, karma and the universe were as much understanding and entrusting me, as they were with him!

Comments are closed.